|
Shin Kawamata
CEO
Cyto-Facto Inc.
Kobe City, Hyogo
Japan
|
Shin studied physics at Kyoto University and medicine at the Kobe University (MD) and received PhD degree from Kyoto University in pathology (1998). He developed human leukemia mouse models at Systemix Co., Palo Alto USA and Stanford University during his postdoctoral period (1998-2001). He became a Chief Scientist in the Foundation for Biomedical Research and Innovation (FBRI, NPO) (2002-2014) and Director of R&D Center for Cell Therapy (2015-2023 March). In April 2023, he became CEO of Cyto-Facto Inc. He is secretory of ISCT Asia (2000-present). Stem cell biology and cell process are his major interest.